CRISPR*-Cas9 is the ideal gene-editing system for the establishment of disease-relevant models, as it allows the modification of cells in their pluripotent state. However, the single base-pair mutations induced by this system are too small to support the use of screening genes. This means that many clones must be sequenced in order to identify those that contain your desired mutation; increasing the time spend optimizing cell culture conditions.
*Clustered Regular Interspaced Short Palindromic Repeats.
Figure 1: How to generate a clinically relevant disease model for drug discovery.
The development of SNIPER† has overcome this obstacle by increasing the number of positive clones detected during the initial screening process. In fact, SNIPER is so accurate it can increase the fraction of positive clones detected 300-fold, reducing the number of cells for sequencing. In collaboration with GenAhead Bio®, REPROCELL can now offer CRISPER-SNIPER as part of our stem cell services.
† Specification of Newly Integrated Position and Exclusion of Random-Integration.
The addition of SNIPER to you CRISPR gene-editing allows:
In our SNIPER projects, REPROCELL also include an isogeneic control to assess the effect of your genetic mutation on disease phenotype. This not only assists the identification of novel test agents but provides a control line for the assessment of drugs tested in your custom model system. You can read more about the advantages of the CRISPR-SNIPER system here.
At REPROCELL we are committed to the advancement of human health through biomedical innovation and discovery. You can learn more about the science behind SNIPER in our interview with its creator, Dr Tsukasa Sugo, or in our BioInformant article by Cade Hildreth: “Development of iPSC-derived disease models”.